Breast Cancer Clinical Trial
Official title:
Pink Warrior—Support Group Toolkit for Breast Cancer Survivors
NCT number | NCT02750241 |
Other study ID # | 16-0040 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | January 2019 |
Verified date | December 2019 |
Source | The University of Texas Medical Branch, Galveston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breast cancer survivors, from diagnosis until the end of life, go through many transitions.
One major transition is the significant decrease of physical activity immediately after
diagnosis. Despite the known benefits of physical activity—speeding recovery time and reduced
cancer recurrence risk—only 1 in 3 survivors met physical activity recommendations of 150
minutes of moderate-intensity activity per week. Physical activity interventions have shown
effectiveness in helping breast cancer survivors increase physical activity during treatment,
but limited evidence-based physical activity interventions have been incorporated into the
clinic and community. To address this limitation, the investigators are partnering with the
UTMB breast cancer support group to conduct a 12-week physical activity intervention, Pink
Warrior.
The goal of this study is to compare an intervention that uses active games versus an
intervention uses pedometer to encourage physical activity such as walking within breast
cancer survivors in active cancer treatment. The study will include breast cancer survivor
between the ages of 18 - 70 whom currently gets less than 150 minutes of planned physical
activity per week and received a breast cancer diagnosis within 0 to 6 months. Participants
will be randomized to participate in the support group using the active video game-based
physical activity intervention (Wii and Xbox active games) or to participate in the existing
UTMB breast cancer support group with pedometers (Digi-Walker CW-700/701). The investigators
hypothesize that by engaging in active video gaming, breast cancer survivors will be
motivated to initiate and maintain physical activity during treatment. This will ultimately
increase functional capacity and prevent functional disability in breast cancer survivors.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Provide informed consent 2. Diagnosed with primary female breast cancer within 0 to 6 months period of time 3. English-speaking between the ages of 18 and 70 4. Able to read and write in English 5. Obtained approval from oncologists for the participant to be involved in the physical activity based support group 6. Able to travel to the UTMB Breast Health Center 7. Able to move arms and legs as well as ambulate 8. Able to see TV screen from a distance of 2 to 4 feet Exclusion Criteria: 1. Being pregnant 2. Dementia 3. Currently engage in =150 minutes of planned moderate physical activity per week for the prior week 4. Are involved in another physical activity intervention |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Medical Branch | Galveston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Medical Branch, Galveston |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in weight | Change in body weight between 14 weeks and baseline as measured by a weight scale in the clinic | Change in weight from baseline to 14 weeks | |
Other | Change in waist circumference | Change in waist circumference between 14 weeks and baseline as measured by Seca-203 | Change in waist circumference from baseline to 14 weeks | |
Other | Change in physical activity minutes, measured by the Community Healthy Activities Model Program for Seniors | Self-reported physical activity questionnaire | Change in physical activity minutes from baseline to 14 weeks | |
Other | Change in physical function, measured by PROMIS measure specific to cancer survivors | Changes in overall self-reported physical functions between 14 weeks and baseline as measured by PROMIS-Ca Bank v1.1-Physical Function | Change in physical function from baseline to 14 weeks | |
Other | Change in fatigue, measured by PROMIS measure specific to cancer survivors | Changes in overall self-reported fatigue level between 14 weeks and baseline as measured by PROMIS-Ca Bank v1.1-Fatigue | Change in fatigue from baseline to 14 weeks | |
Other | Change in exercise motivation, measured by autonomous motivation specific to physical activity | Behavioral regulation in Exercise Questionnaire-2 will be used | Change in motivation from baseline to 14 weeks | |
Other | Change in psychological feelings, measured by Psychological Need Satisfaction in Exercise Scale | Sub-scales included perceived competence, perceived autonomy, and perceived relatedness | Change in psychological feelings from baseline to 14 weeks | |
Other | Change in self-regulation, measured by Rovinak et al. scale | Sub-scales include exercise goals and exercise plans | Change in self-regulation from baseline to 14 weeks | |
Other | Feasibility-Adherence | Adherence will be measured by number of participants who completed at least 80% of the program activities. | 14 weeks | |
Other | Feasibility-Attrition | Attrition will be measured by percentage of people who dropped out of the intervention program. | 14 weeks | |
Other | Feasibility-Technological Issues | Technological issues will be measured by counting number of occurrence | 14 weeks | |
Other | Feasibility-Adverse Events | Adverse events will be measured by counting number of occurrence | 14 weeks | |
Other | Acceptability | Participant acceptability and satisfaction will be assessed by a questionnaire with 5-point scale responses | 14 weeks | |
Primary | Change in physical activity steps per day as measured by an Actigraph monitor | Change in steps per day between 14 weeks and baseline as measured by an Actigraph monitor | Change in steps per day from baseline to 14 weeks | |
Primary | Change in physical activity minutes as measured by an Actigraph monitor | Change in physical activity minutes between 14 weeks and baseline as measured by an Actigraph monitor | Change in physical activity minutes from baseline to 14 weeks | |
Secondary | Change in physical function as measured by the Short Physical Performance Battery (SPPB) | The SPPB consists of six components: repeated chair sit and stands, balance test, semi-tandem stand, tandem stand, side-by-side stand, and eight feet walk | Change in physical function from baseline and 14 weeks | |
Secondary | Change in dietary pattern as measured by the Dietary Screener Questionnaire | Change in dietary pattern from baseline and 14 weeks] [Safety Issue: No] The Dietary Screener Questionnaire used in the National Health and Nutrition Examination Survey 2009-10. The screener captures frequency of fruits, vegetables, dairy/calcium, added sugar, whole grains/fiber, red meat, and processed meat consumption within the past 30 days | Change in dietary pattern from baseline and 14 weeks | |
Secondary | Change in quality of life as measured by the Functional Assessment of Cancer Therapy-Breast measure | Changes in physical, social, emotional, functional, and additional well-being between 14 weeks and baseline as measured by FACT-B | Change in quality of life from baseline and 14 weeks | |
Secondary | Change in hand grip strength as measured by hand dynamometer | Hand dynamometer estimates the muscle strength generated from flexor muscles of the hand and the forearm | Change in hand grip strength from baseline to 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |